Table 6.

AI Based drug repurposing application on networks.

	Title	Datasets used	Repurposed Drugs	Evaluation Criteria	Tools used	Ref.
1	Network medicine framework for identifying drug-repurposing opportunities for COVID-19	13 Datasets, DrugBank, STRING	989 Drugs, 77 Validated in VeroE6 Cells, 76/77 validated in Human Cells	Network proximity, network diffusion, Network AI	Experimental, Ensembl algorithmic prediction	[176]
2	Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence	CTDbase, STRING, Hetionet, DrugBank	22 drugs and drug combinations	Validation with multiple sources, In-vitro screening	GSEA, Plotly, Gephi, GNN	[178]
3	COVID-19 Multi-Targeted Drug Repurposing Using Few-Shot Learning	Chemical Molecules, ZINC, ChEMBL,	–	Loss function and metrics	Few-shot learning	[179]
4	Machine learning and network medicine approaches for drug repositioning for COVID-19	STRING, ChEMBL, DrugBank	–	In-vitro, In-vivo, clinical trials, and CMAP	–	[180]
5	Using informative features in machine learning based method for COVID-19 drug repurposing	STRING, DrugBank, Uniprot	80 % of the predictions were verified	Statistical and clinical evidence	Enrichment analysis,	[182]
6	An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	Literature, DrugBank, CTD, Uniprot, CMap	41 Drugs	wet-lab, Expression profiles of patients and drug perturbation cells, clinical trials data	Molecular docking	[183]
7	Network-based repurposing identifies anti-alarmins as drug candidates to control severe lung inflammation in COVID-19	Uniprot, STRING, CMap, LINCS, GEO	–	Gene expression profiling, CMap ranking	LINCS tools	[184]
8	Drug repurposing for COVID-19 via knowledge graph completion	PubMed and Covid-19 research literature, ClinicalTrials.gov	5 Drugs	ClinicalTrials.gov	–	[185]
9	Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease	PolypharmDB, DrugBank, STRING	26 Drugs	Infectivity assays, combination of human coronavirus entry and infection assays	MatchMaker	[186]